Literature DB >> 1506772

Type I interferons (IFN-alpha and -beta) suppress cytotoxin (tumor necrosis factor-alpha and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cell.

K S Abu-Khabar1, J A Armstrong, M Ho.   

Abstract

We studied the effect of the different types of interferons on the production of cytotoxin by human peripheral blood mononuclear cells (PBMCs) stimulated with the mitogen phytohemagglutinin (PHA). Maximum secreted levels of cytotoxin were observed at day 3 in culture and consisted of both tumor necrosis factor alpha (TNF-alpha) and lymphotoxin as determined by specific antibodies. Type I interferons (IFN-alpha and IFN-beta) consistently suppressed cytotoxin production. Both TNF-alpha and lymphotoxin were significantly suppressed. Mean suppression by IFN-alpha and IFN-beta (1000 U/ml) was 56 and 66%, respectively, in PBMCs from 18 different donors. The suppressive effects of IFN-alpha and IFN-beta on cytotoxin production were dose responsive over a range of 10 to 1000 U/ml. Type II interferon (IFN-gamma) did not have consistent significant effects. Pretreatment with IFN-alpha or IFN-beta for 24 or 48 h prior to PHA stimulation also resulted in significant suppression. Supplementation with interleukin-2 (10 U/ml) or IFN-gamma (1000 U/ml) did not overcome cytotoxin suppression by IFN-alpha or IFN-beta. Cytotoxin suppression by IFN-alpha and IFN-beta together appeared to be noninteractive. Suppression appeared not to be due to blockade of the cytotoxin release, since both cell-associated cytotoxin and secreted cytotoxin were suppressed to the same level. These results demonstrated that cytotoxin and lymphotoxin production by PHA-stimulated PBMCs could be down-regulated by type I interferons and that there is a substantial difference between the action of type I interferons and type II interferons (IFN-gamma) in modulating the biosynthesis of cytotoxins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1506772     DOI: 10.1002/jlb.52.2.165

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

1.  Correlation between interferon production and clinical disease activity in patients with multiple sclerosis.

Authors:  M Dettke; P Scheidt; H Prange; H Kirchner
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

2.  Effect of anticoagulants on binding and neutralization of lipopolysaccharide by the peptide immunoglobulin conjugate CAP18(106-138)-immunoglobulin G in whole blood.

Authors:  M Ogata; M F Fletcher; M Kloczewiak; P M Loiselle; E M Zanzot; M W Vermeulen; H S Warren
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

Review 3.  Post-transcriptional control of the interferon system.

Authors:  Khalid S A Khabar; Howard A Young
Journal:  Biochimie       Date:  2007-02-24       Impact factor: 4.079

4.  Expression of beta-defensin genes in bovine alveolar macrophages.

Authors:  L K Ryan; J Rhodes; M Bhat; G Diamond
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

5.  Dynamic production of tumour necrosis factor-alpha (TNF-alpha) messenger RNA, intracellular and extracellular TNF-alpha by murine macrophages and possible association with protein tyrosine phosphorylation of STAT1 alpha and ERK2 as an early signal.

Authors:  Z M Zheng; S Specter
Journal:  Immunology       Date:  1996-04       Impact factor: 7.397

6.  Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte response.

Authors:  Shirin Munir; Philippa Hillyer; Cyril Le Nouën; Ursula J Buchholz; Ronald L Rabin; Peter L Collins; Alexander Bukreyev
Journal:  PLoS Pathog       Date:  2011-04-21       Impact factor: 6.823

Review 7.  Anti-inflammatory properties of Type I interferons.

Authors:  Alfons Billiau
Journal:  Antiviral Res       Date:  2006-04-04       Impact factor: 5.970

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.